Alamar Biosciences, Inc. (NASDAQ:ALMR – Get Free Report) major shareholder Corporate Gp Vi Ltd. Qiming sold 100,837 shares of the firm’s stock in a transaction that occurred on Wednesday, October 28th. The shares were sold at an average price of $32.77, for a total value of $3,304,428.49. Following the completion of the sale, the insider directly owned 164,191 shares of the company’s stock, valued at $5,380,539.07. This trade represents a 38.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):
- On Tuesday, October 27th, Corporate Gp Vi Ltd. Qiming sold 84,894 shares of Alamar Biosciences stock. The shares were sold at an average price of $31.39, for a total value of $2,664,822.66.
- On Monday, October 26th, Corporate Gp Vi Ltd. Qiming sold 132,524 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.52, for a total value of $4,044,632.48.
- On Friday, October 23rd, Corporate Gp Vi Ltd. Qiming sold 147,934 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.59, for a total value of $4,525,301.06.
- On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The stock was sold at an average price of $29.33, for a total value of $3,924,676.63.
- On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.31, for a total value of $6,329,182.65.
- On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.89, for a total transaction of $3,960,491.56.
- On Monday, October 19th, Corporate Gp Vi Ltd. Qiming sold 75,508 shares of Alamar Biosciences stock. The stock was sold at an average price of $26.34, for a total transaction of $1,988,880.72.
- On Friday, October 16th, Corporate Gp Vi Ltd. Qiming sold 136 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.02, for a total transaction of $3,674.72.
- On Thursday, October 15th, Corporate Gp Vi Ltd. Qiming sold 173,537 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.73, for a total transaction of $4,812,181.01.
Alamar Biosciences Price Performance
Alamar Biosciences stock opened at $34.04 on Friday. The company’s 50 day moving average is $30.73. The company has a quick ratio of 10.23, a current ratio of 11.85 and a debt-to-equity ratio of 0.03. Alamar Biosciences, Inc. has a twelve month low of $18.84 and a twelve month high of $39.61.
Alamar Biosciences (NASDAQ:ALMR – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.14. The company had revenue of $29.43 million during the quarter. On average, research analysts predict that Alamar Biosciences, Inc. will post -1.22 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on ALMR. Weiss Ratings cut Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, October 23rd. TD Cowen reissued a “buy” rating on shares of Alamar Biosciences in a report on Wednesday, July 15th. JPMorgan Chase & Co. boosted their price objective on Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Finally, Stifel Nicolaus upped their price objective on shares of Alamar Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $31.80.
Get Our Latest Stock Analysis on Alamar Biosciences
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of ALMR. Sumitomo Mitsui Trust Group Inc. raised its holdings in Alamar Biosciences by 18.5% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company’s stock valued at $2,280,000 after acquiring an additional 10,461 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in shares of Alamar Biosciences in the third quarter worth $196,000. State Street Corp bought a new position in shares of Alamar Biosciences in the second quarter worth $3,930,000. Squarepoint Ops LLC purchased a new position in shares of Alamar Biosciences in the second quarter valued at $283,000. Finally, Braidwell LP purchased a new position in shares of Alamar Biosciences in the second quarter valued at $29,365,000.
Alamar Biosciences News Summary
Here are the key news stories impacting Alamar Biosciences this week:
- Positive Sentiment: Strong ALS study validates Alamar’s technology. Emory researchers reported that a 10-protein blood signature detected ALS with 98.3% accuracy and outperformed a leading individual biomarker, including in difficult-to-diagnose cases. Publication in Nature Communications could improve the visibility and commercial credibility of Alamar’s NULISA proteomics platform. Alamar Biosciences’ Protein Signature Detects ALS With 98.3% Accuracy in Study
- Neutral Sentiment: Analyst views remain mixed. Earlier upgrades from Stifel and JPMorgan set price targets of $32 and $35, respectively, while Weiss Ratings downgraded the stock to sell. The broader analyst consensus is “Hold,” with an average target of $31.80, below the company’s recent trading range. Alamar remains unprofitable, although its latest quarterly loss was narrower than expected and revenue totaled $29.43 million.
- Negative Sentiment: Major shareholder Qiming continued a substantial selling program. Corporate GP VI Ltd. Qiming sold 100,837 shares on October 28 and 84,894 shares on October 27, following additional sales on October 26 and earlier dates. Across the reported transactions from October 15 through October 28, the shareholder sold approximately 1.2 million shares, reducing its position to 164,191 shares. The repeated insider-related selling may weigh on sentiment and suggests a significant near-term supply overhang. Alamar Biosciences SEC Insider Sale Filing
About Alamar Biosciences
Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.
Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.
Featured Stories
- Five stocks we like better than Alamar Biosciences
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Alamar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alamar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
